Compare EJH & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EJH | ASBP |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.6M |
| IPO Year | 2019 | N/A |
| Metric | EJH | ASBP |
|---|---|---|
| Price | $1.80 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 832.9K | 526.8K |
| Earning Date | 05-18-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.05 |
| 52 Week High | $12.45 | $2.45 |
| Indicator | EJH | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 53.58 |
| Support Level | $0.84 | $0.32 |
| Resistance Level | $2.80 | $1.29 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 63.67 | 74.47 |
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving orders online and providing services offline. Its operations are organized into four reportable segments: appliance installation and maintenance services, housekeeping services, senior care services, and educational consulting services. The company generates the majority of its revenue from installation and maintenance.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.